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Abstract
Introduction: Post-stroke hypoxia is common, and may adversely affect outcome. We have recently shown that oxygen
supplementation may improve early neurological recovery. Here, we report the six-month outcomes of this pilot study.
Methods: Patients with a clinical diagnosis of acute stroke were randomized within 24 h of admission to oxygen
supplementation at 2 or 3 L/min for 72 h or to control treatment (room air). Outcomes (see below) were assessed by postal
questionnaire at 6 months. Analysis was by intention-to-treat, and statistical significance was set at p#0.05.
Results: Out of 301 patients randomized two refused/withdrew consent and 289 (148 in the oxygen and 141 in the control
group) were included in the analysis: males 44%, 51%; mean (SD) age 73 (12), 71 (12); median (IQR) National Institutes of
Health Stroke Scale score 6 (3, 10), 5 (3, 10) for the two groups respectively. At six months 22 (15%) patients in the oxygen
group and 20 (14%) in the control group had died; mean survival in both groups was 162 days (p= 0.99). Median (IQR)
scores for the primary outcome, the modified Rankin Scale, were 3 (1, 5) and 3 (1, 4) for the oxygen and control groups
respectively. The covariate-adjusted odds ratio was 1.04 (95% CI 0.67, 1.60), indicating that the odds of a lower (i.e. better)
score were non-significantly higher in the oxygen group (p= 0.86). The mean differences in the ability to perform basic
(Barthel Index) and extended activities of daily living (NEADL), and quality of life (EuroQol) were also non-significant.
Conclusions: None of the key outcomes differed at 6 months between the groups. Although not statistically significant and
generally of small magnitude, the effects were predominantly in favour of the oxygen group; a larger trial, powered to show
differences in longer-term functional outcomes, is now on-going.
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Introduction
Hypoxia is common after acute stroke and may have significant
adverse effects on the ischaemic brain [1–3]. Hypoxia is
particularly likely to occur at times when the patient tends not
to be observed so closely, e.g. during the head scan, during transfer
from the emergency department to the ward, and at night [3]. In
an acute stroke unit, where oxygen saturation was assessed every
six hours, 52% of stroke patients with normal oxygen saturation in
the day had five minutes or more of hypoxia (oxygen saturation
lower than 90%) at night on analysis of continuous pulse oximetry;
23% were hypoxic for more than 30 min, and 15% for more than
1 h [4]. While continuous pulse oximetry is available in most, if
not all, UK stroke units, it is marred by frequent false alarms due
to displacement of the finger probe. Reliable detection of hypoxia
by this means requires a quasi-intensive care environment with a
nurse free to check every desaturation alarm immediately. Prompt
and effective treatment of hypoxia may be one of the reasons why
patients nursed on a stroke unit have better outcomes. Such
patients are more likely to receive oxygen than on a non-
specialized general ward [5]. Treating all episodes of hypoxia with
supplemental oxygen has been identified as one of three key
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processes associated with better outcome in acute stroke care [6].
Routine oxygen supplementation during the first few days after the
stroke, when the ischaemic brain is most vulnerable, could be an
effective method of reducing the hypoxic burden and improving
outcome. The aim of the Stroke Oxygen Pilot Study is to
determine whether low-flow oxygen at a rate of 2 or 3 L/min,
dependent on baseline oxygen saturation, with the intention to
keep oxygen saturation within the normal range over a period of
72 hours, improves outcome after acute stroke. Week one results
of the study suggest that early neurological recovery may be
improved by oxygen supplementation [7]. In this paper we present
functional and quality of life outcomes of this study at six months;
the study is reported in line with the CONSORT statement [8].
Methods
Design, recruitment, intervention, and baseline
assessments
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
This is a randomized controlled single-blind pilot study of
routine oxygen supplementation after acute stroke. Detailed
methodology and neurological outcome at one week have
previously been reported [7]. In this paper we present the long-
term (six-month) outcomes. In short, adult patients with a clinical
diagnosis of acute stroke as defined by the World Health
Organization [9] were eligible for inclusion if they were admitted
to the University Hospital of North Staffordshire within the
preceding 24 hours, were able to give informed consent, or a
relative was contactable and willing to give assent, and if there was
no clear indication for or against oxygen treatment. Recognized
indications for oxygen treatment were: oxygen saturation on air
,90%, acute left ventricular failure, severe pneumonia, pulmo-
nary embolus, and chronic respiratory failure treated with long-
term oxygen at home. We excluded patients with contraindica-
tions to fixed-dose oxygen treatment at a rate of 2 or 3 L/min (e.g.
type II respiratory failure), patients where stroke was not the
primary clinical problem, and patients with other serious life-
threatening illnesses likely to lead to death within a few months. As
this was a pilot study, the sample size was not determined through
a formal power calculation, but what was achievable within
available resources.
Participants were randomized to two treatment arms: (1)
Oxygen via nasal cannulae at a flow rate of 2 L/min if baseline
oxygen saturation (SpO2) was greater than 93% or 3 L/min if
baseline SpO2 was 93% or less for a period of 72 hours. (2)
Control (oxygen only when clinically indicated). Randomization
was by telephone or web portal access to a remote centre, and
employed a computerized randomization algorithm. Heart rate,
blood pressure, and SpO2 were assessed regularly (at least three
times a day) as part of routine clinical care. Those participants who
developed indications for oxygen, or needed a higher concentra-
tion of oxygen than the protocol prescribed, were given the
appropriate concentration of oxygen by the treating clinician,
irrespective of the treatment group. Baseline demographic and
clinical details were established by interview and consultation of
the medical notes and included the Oxfordshire Community
Project Stoke Classification [10], oxygen saturation on room air,
the National Institutes of Health Stroke Scale (NIHSS) [11] and
the result of the computed tomography (CT) head scan. Using the
‘six simple variables’ (SSVs) in the SCOPE predictive model
[13,14], we also calculated two prognostic indices: (i) the
probability of being free of dependency at six months (defined as
a modified Rankin Scale (mRS) [12] less than 3) and (ii) the
probability of survival at 30 days. The indices for this predictive
model are derived from the patient’s age and five dichotomous
variables: living alone before stroke; independent before stroke;
normal verbal response on the Glasgow Coma Scale [15]; ability
to lift the arm against gravity; and ability to walk unaided.
Six-month outcomes
Data were obtained using a postal questionnaire 6 months post
stroke. Participants were invited to complete the questionnaire
personally or with help from a family member or carer; this was
recorded on the questionnaire. The primary outcome measure for
this study was the mRS at 6 months [12]. This ordinal scale
measures the degree of disability and dependence post stroke.
Other measures included the abbreviated 3-item Barthel Index
[16], the EuroQol standardized quality of life scale [17,18], and
the Nottingham Extended Activities of Daily Living Scale
(NEADL) [19]. The 3-item Barthel Index covers continence, bed
to chair transfers, and mobility, with scores ranging from 0 (unable
to do these activities) to 8 (able to do all independently). We used
the formula ([total 3-item score]62.39)+0.14 [16] to convert this to
the more commonly used 10-item (20-point) Barthel Index [20].
The EuroQol describes quality of life in five dimensions (EQ-5D):
mobility, self-care, usual activities, pain/discomfort and anxiety/
depression. Each is scored as 1 (no problem), 2 (some problems), or
3 (not able/extreme). For analysis, scores from the five dimensions
were combined into a single utility score. This score can be
adjusted according to different population based weightings; here
we used the weighting scheme derived for the UK [17], giving a
possible range of scores from 20.59 to 1.00. The EQ-5D is
accompanied by a visual analogue scale (EQ-VAS) on which
participants self-rate their heath from 0 (worst imaginable health
state) to 100 (best imaginable health state). The NEADL assesses
the ability of participants to perform 20 extended activities of daily
living, covering mobility, kitchen, domestic, and leisure activities.
Each activity allows four responses: able to perform this alone
easily (1), alone with difficulty (2), with help (3), and not all (4),
giving a summated range of scores from 20 (able to do all activities
easily) to 80 (unable to do any of the activities).
Statistical analysis
Data were analysed on an intention-to-treat basis, and for each
outcome the covariate-adjusted analysis was designated as the
primary analysis; covariates were selected a priori on the basis of
their clinical and prognostic importance. Missing values on the
outcome measures were imputed through multiple imputation,
under a missing-at-random assumption, using six imputed
datasets. A sensitivity analysis was also performed using only cases
with complete follow-up data [21].
Between-group differences on the primary outcome, the mRS,
and the Barthel Index were analysed by proportional odds ordinal
logistic regression (with the oxygen group as reference category),
adjusting for the following covariates: age, sex, probability of being
free from dependency at 6 months, oxygen saturation at
randomization, type of stroke, and baseline values of the NIHSS.
The Barthel Index and the NEADL were analysed through
analysis of covariance, adjusting for the same covariates. Baseline
data were not available for any of these outcome measures and no
adjustment was therefore possible.
For 6-month survival, a log-rank test was performed for an
unadjusted analysis. For an adjusted analysis, a Cox proportional-
hazards regression model was used, with these covariates: age, sex,
probability of 30-day survival, oxygen saturation at randomiza-
tion, type of stroke, and baseline values of the NIHSS. The
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proportional hazards assumption was tested via Schoenfeld
residuals and found to be tenable (p=0.72).
Data were analysed in SPSS v20 (IBM, Armonk NY, USA) and
imputations were performed in SOLAS 2 (Statistical Solutions,
Cork, Ireland). Statistical significance was set at p#.05 (two-tailed)
and 95% confidence intervals (CIs) were calculated for all estimates.
Ethical approval, trial registration, and consent
The protocol was approved by the North Staffordshire
Research Ethics Committee on 06.10.2004 (ref: 04/Q2604/73).
It is registered in the International Standard Randomized
Controlled Trial Number Register (ISRCTN12362720) and the
European Clinical Trials Database (EudraCT number 2004-
001866-41). Written informed consent was sought from all study
participants. Assent from the next of kin was accepted if the patient
agreed to take part but was unable to give fully informed consent.
Participants who were incompetent at the time of recruitment, but
competent when followed-up at 1 week were asked to confirm
consent. Patients who were recruited to the study by assent and
refused consent at 1 week were withdrawn from the study.
Requests for the trial data should be addressed to the
corresponding author.
Results
Recruitment
The flow of patients through each stage of the study has
previously been published for the week one results [7] and is the
same for the main follow-up at 6 months (Figure 1). Three
hundred and one patients were recruited to the study from
October 2004 to April 2008. A total of 155 patients were allocated
to oxygen and 146 to control. All randomized participants were
subsequently given the allocated treatment. In 6 participants in the
oxygen group and 4 in the control group, the initial clinical
diagnosis of stroke was shown to be incorrect after further
investigation (brain tumour n=7, motor neurone disease n=1,
possible multiple sclerosis n=1, no final diagnosis n=1). One
patient in each treatment group was excluded due to withdrawal of
consent, leaving 148 and 141 subjects in the oxygen and control
group to be considered in the final analysis.
Baseline characteristics
Baseline clinical and demographic characteristics of the groups
are shown in Table 1. Most variables were well balanced across
groups, except for age, gender, probability of being free from
dependency at 6 months, and baseline NIHSS, with the oxygen
group having a higher mean age, more females, a lower
probability of being free from dependency at 6 months, and a
higher baseline median NIHSS score.
Who completed the 6 month questionnaire?
The questionnaire was completed in 112 and 111 participants
(89% and 92% of survivors) in the oxygen and control groups
respectively. Only just over a third completed the questionnaires
unaided (Table 2). There were missing values on the modified
Rankin scale (33 values), the EQ-5D (67 values) and EQ-VAS (112
values), the NEADL (96 values), and the Barthel Index (62 values).
The Modified Rankin Scale
This scale was completed for 126 (85%) and 130 (92%)
participants in the oxygen and control groups respectively. The
number of participants independent at six months (mRS,3) was
56 (44%) and 58 (45%) in the oxygen and control groups
respectively. The median (IQR) values on the mRS at six months
were virtually the same in both groups: 3 (1, 4) for oxygen and 3 (1,
5) for control. From the ordinal regression analysis, the covariate-
adjusted odds ratio was 1.04 (95% CI 0.67, 1.60); this favoured the
oxygen group, indicating that the odds for a better (i.e. lower) score
on the mRS were 4% higher in the oxygen group than in controls,
but the difference was non-significant (p=0.86). The correspond-
ing odds ratio without adjustment was 0.95 (95% CI 0.62, 1.46;
p=0.82). The distribution of scores on the mRS is shown in
Figure 2. While there was no difference between the groups for the
milder mRS Scores (0–2), there appeared to be a shift at the more
severe end, with fewer patients in the oxygen group being totally
dependent (mRS of 5).
The Barthel Index
This assessment was completed for 114 (77%) and 113 (80%)
participants in the oxygen and control groups respectively. The
median (IQR) score on the 3-point Barthel was 6 (5, 8) for the
oxygen and 7 (6, 8) for the control group. Using the conversion
formula (see Methods), the median scores on the 20-point scale
were 14 and 17, respectively. The majority of respondents were
fully continent (60 [53%] vs. 72 [64%]), independent in bed to
chair transfers (71 [62%] vs. 81 [72%]) and able to able to
mobilize independently (58 [51%] vs. 70 [62%]), for oxygen and
control respectively (see Table 3). The covariate-adjusted odds
ratio from the ordinal regression analysis was 1.50 (95% CI 0.94,
2.37); this favours the control group, indicating that the odds for a
worse (i.e. lower) score on the Barthel Index were 50% higher in
the oxygen group than in controls, but not significantly (p=0.09).
The corresponding unadjusted odds ratio was just significant: 1.54
(95% CI 1.00, 2.38; p=0.05).
The Nottingham Extended Activities of Daily Living Scale
This assessment was completed for 93 (63%) and 100 (71%)
participants in the oxygen and control groups respectively. The
covariate-adjusted means in the oxygen and control groups were
47.62 and 49.23 respectively, giving an adjusted mean difference
(control minus oxygen) in ability scores of 1.59 (95% CI 23.26,
6.45), in favour of the oxygen group. This difference was not
significant (p=0.52). The mean unadjusted scores for the oxygen
and control groups were 48.39 and 48.47 respectively, giving a
mean difference of 20.08 (95% CI 25.34, 5.51; p=0.98).
Combining scores for all 20 tasks, the mean percentage of subjectsFigure 1. Flow of patients through the study.
doi:10.1371/journal.pone.0059274.g001
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able to perform the activities alone was 55% in the oxygen group
and 58% in the control group (Table 4).
Quality of life (EuroQol)
EQ-5D scores were obtained for 110 (74%) and 112 (79%)
participants and EQ-VAS scores for in 81 (55%) and 96 (68%)
participants, in the oxygen and control groups respectively. Scores
on the individual dimensions are summarized in Table 5. The
covariate-adjusted mean EQ-5D utility scores in the oxygen and
control groups were 0.50 and 0.49 respectively, giving an adjusted
mean difference (control minus oxygen) in utility scores of 20.01
(95% CI 20.10, 0.07), in favour of the oxygen group (p=0.79).
The unadjusted mean scores for the oxygen and control groups
were 0.50 and 0.50 respectively, giving a mean difference of 0.00
(95% CI 20.09, 0.09; p=0.99).
The covariate-adjusted mean scores for the EQ-VAS were
59.24 and 54.84 for the oxygen and control groups respectively,
giving an adjusted mean difference (control minus oxygen) of
Table 1. Baseline characteristics.
Oxygen (n=148) Control (n=141)
Demographic characteristics
Age in years; mean (SD) 73 (12) 71 (12)
Male gender; n (%) 65 (44) 72 (51)
Prognostic factors
Living alone; n (%) 61 (41) 52 (37)
Independent in basic activities of daily living; n (%) 122 (82) 121 (86)
Normal verbal response; n (%) 102 (69) 92 (65)
Able to lift affected arm; n (%) 92 (62) 92 (65)
Able to walk; n (%) 20 (14) 21 (15)
Probability: non-dependent at 6 months; median (IQR) 0.19 (0.02, 0.55) 0.27 (0.03, 0.66)
Probability: 30-day survival; median (IQR) 0.23 (0.15, 0.40) 0.23 (0.13, 0.37)
Concomitant medical problems
Ischaemic heart disease; n (%) 34 (23) 37 (26)
Left ventricular failure; n (%) 16 (11) 18 (13)
Atrial fibrillation; n (%) 34 (23) 19 (14)
Chronic obstructive pulmonary disease/asthma; n (%) 14 (10) 12 (9)
Details of the stroke
Time (hh:mm) since stroke; mean (SD) 17:48 (8:46) 16:31 (8:08)
Hemiparesis; n (%)
Right 59 (40) 61 (43)
Left 76 (51) 66 (47)
None 11 (7) 14 (10)
Aetiology; n (%)a
Ischaemic stroke 136 (91) 121 (86
Haemorrhagic stroke 9 (6) 15 (11)
Not established 3 (2) 5 (4)
Total anterior circulation syndrome; n (%) 71 (51) 71 (51)
Glasgow Coma Scale score (3–15); (median, IQR) 15 (15, 15) 15 (15, 15)
NIHSS score (0–42); median (IQR) 6 (3, 10) 5 (3, 10)
Oxygen saturation at randomization; % mean (SD) 96.1 (1.9) 96.1 (2.0)
aPatients presenting with symptoms of stroke were defined as infarcts when the computed tomogram (CT) of the head showed no evidence of an alternative diagnosis.
A diagnosis of haemorrhage included intracerebral, subdural and subarachnoid haemorrhages. Aetiology could not be established in cases where a CT was not
performed. SD= standard deviation; IQR = interquartile range; NIHSS =National Institutes for Health Stroke Scale.
doi:10.1371/journal.pone.0059274.t001
Table 2. Completion of the six-month questionnaire.
Oxygen Control
n=126 n=121
Participant completed it on his/
her own
45 (35) 42 (35)
Completed with help from a
relative/friend
18 (14) 21 (17)
Completed by a relative/friend 25 (20) 37 (31)
Completed by the researcher via
phone, notes, clinic, ward
24 (20) 11 (9)
Question not answered 14 (11) 10 (8)
Data are number (%). Only survivors are included.
doi:10.1371/journal.pone.0059274.t002
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24.40 (95% CI 211.43, 2.63), in favour of the oxygen group
(p=0.22). The corresponding unadjusted means scores were 58.85
and 55.33 giving a mean difference of 23.52 (95% CI 210.88,
3.85; p=0.35); owing to the high rate of missing data (39%) for the
EQ-VAS, these estimates should be interpreted with caution.
Six-month survival
At six months, 22 (15%) patients had died in the oxygen group
and 21 (15%) had died in the oxygen group. Mean survival time at
six months was 162 days for both groups (log-rank test, p=0.99);
see Figure 3. In the adjusted analysis using Cox regression, the
hazard function was 1.10 (95% CI 0.59, 2.07), suggesting that
those in the control group had a slightly higher probability of
dying at a given time; however, this hazard ratio was non-
significant (p=0.76).
Memory
Memory was reported as ‘‘as good as before the stroke’’ in 51 (53%)
and 46 (45%) and as ‘‘worse than before the stroke’’ in 45 (47%) and
56 (55%) of the 96 and 102 respondents to this question respec-
tively in the oxygen and control groups (exact x2=1.28, p=0.32).
Place of residence
At six months 98 (83%) and 104 (92%) of the 113 and 118
respondents in the oxygen and control groups respectively resided
in a private house (alone or with relatives), 19 (16%) and 8 (7%)
were in an institution (nursing home or residential home), and 1
(1%) and 1 (1%) were still in hospital (exact x2 = 4.55, p=0.08).
Sensitivity analyses
A sensitivity analysis using only participants with complete
follow-up data was performed for the mRS, the Barthel Index, the
NEADL, and the EuroQol. These analyses produced very similar
estimates to the intention-to-treat analyses, and the statistical
conclusions were unchanged (see Table 6).
Discussion
The main finding of this pilot study is that supplemental oxygen
given for 72 h after stroke is safe, but has no large effect on
measures of the level of disability, the ability to perform basic and
extended activities of daily living, quality of life, and place of
residence at six months.
Figure 2. Distribution of modified Rankin Scale scores in each treatment group. Key. 0: No symptoms at all, 1: No significant disability
despite symptoms, able to carry out all usual duties and activities, 2: Slight disability; unable to carry out all previous activities, but able to look after
own affairs without assistance, 3: Moderate disability; requiring some help, but able to walk without assistance, 4: Moderately severe disability; unable
to walk without assistance and unable to attend to own bodily needs without assistance, 5: Severe disability; bedridden, incontinent and requiring
constant nursing care and attention, 6: Dead.
doi:10.1371/journal.pone.0059274.g002
Table 3. The abbreviated Barthel Index.
Oxygen Control
n=113 n=114
Bladder 0 Catheterizeda 6 (5) 8 (7)
0 Incontinenta 17 (15) 11(10)
1 Occasional accident 31 (27) 22 (20)
2 Continent 60 (53) 72 (64)
Transfers 0 Unable – no
sitting balance
8 (7) 4 (3)
(bed/chair) 1 Major help
needed
14 (12) 13 (12)
2 Minor help
needed
21 (18) 15 (13)
3 Independent 71 (62) 81 (72)
Mobility 0 Immobile 12 (11) 5 (4)
1 Wheelchair
independent
12 (11) 7 (6)
2 Walks with help
of one person
32 (28) 31 (27)
3 Independent 58 (51) 70 (62)
Data are number (%). Only participants providing data on all three points are
included.
aCatheterized and incontinent are indicated separately, but each was scored as
0.
doi:10.1371/journal.pone.0059274.t003
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Rønning et al have previously shown a similar lack of benefit in
terms of survival and the level of independence in a quasi-
randomized study of low-flow oxygen supplementation at a rate of
3 L/min for 24 h in a sample of 550 stroke patients recruited
within 24 h of symptom onset [22]. Subgroup analysis in this study
suggested possible harm in patients with mild stroke, and potential
benefit in severe stroke. Our pilot study is not powered to exclude
or confirm a differential effect dependent on stroke severity. A very
small pilot study by Singhal et al of high-flow oxygen treatment at
a rate of 45 L/min for 8 h via face mask in 16 patients within 12 h
after acute stroke showed transient improvements in cerebral
blood volume and blood flow within the ischaemic regions with
hyperoxia (higher than normal blood oxygen concentrations), but
no long-term clinical benefit at three months [23]. This study was
followed by a larger trial of the same intervention, which was
stopped after 86 patients were enrolled because of an imbalance of
deaths in favour of the control group (20% on oxygen vs. 8% on
room air). The results are available on the clinicaltrials.gov website
[24], but not published in a journal. This study raises the concern
that not only too low, but also too high oxygen concentrations
could be detrimental. A similar adverse effect of hyperoxia on
mortality has been suggested in a recent meta-analysis (n=387) of
oxygen treatment (4–6 L/min) in myocardial infarction [25] and
in a large (n=6326) observational study of cardiac arrest survivors
in the intensive care unit, where hyperoxia (PaO2 of 300 mmHg
[40 kPa] or greater) increased the odds of in-hospital death by 1.8,
with higher mortality in hyperoxic than in hypoxic (PaO2 of less
than 60 mmHg [8 kPa]) patients [26]. In contrast to these studies,
the dose of oxygen given in the Stroke Oxygen Pilot Study aims to
maintain normoxia, rather than achieve hyperoxia. In the
subsequent main study (the Stroke Oxygen Supplementation
Study: SO2S) [27], we included a third arm, where oxygen is only
given at night, at a time when the risk of hypoxia is highest [28],
thus reducing the chance of hyperoxia in the day, when oxygen
concentrations are more likely to be normal.
We previously reported that routine oxygen supplementation
given for 72 h at a rate of 2 or 3 L/min, dependent on baseline
Table 4. Nottingham Extended Activities of Daily Living.
Oxygen (n=93) Control (n=100)
Mobility
Walk around inside 65 (70) 73 (73)
Climb stairs 50 (54) 59 (59)
Get in and out of car 43 (46) 63 (63)
Walk on uneven ground 43 (46) 56 (56)
Travel on public transport 30 (32) 32 (32)
Drive a car 32 (36) 39 (39)
Eating and Drinking
Manage to feed yourself 78 (84) 88 (88)
Manage to make a hot drink 64 (69) 79 (79)
Take hot drinks from 1 room to
another
58 (62) 68 (68)
Do the washing up 57 (61) 70 (70)
Make yourself a hot snack 59 (64) 68 (68)
Money and Shopping
Manage own money 57 (61) 61 (61)
Do own shopping 31 (33) 37 (37)
Housework
Wash small items of clothing 51 (55) 54 (54)
Do a full clothes wash 45 (48) 48 (48)
Leisure & Communications
Read newspapers & books 74 (80) 80 (80)
Use the telephone 73 (79) 81 (81)
Write letters 47 (51) 48 (48)
Go out socially 39 (42) 32 (32)
Manage own garden 24 (26) 24 (24)
Data are number (%) of participants able to perform the activity alone (easily or
with difficulty). Only participants providing data on all 20 items are included.
doi:10.1371/journal.pone.0059274.t004
Table 5. Quality of life.
Oxygen Control
Responses n=110 n=112
Mobility No problem 34 (31) 30 (27)
Some problems 69 (63) 74 (66)
Not able 7 (6) 8 (7)
Self-care No problem 59 (54) 60 (54)
Some problems 41 (37) 35 (31)
Not able 10 (9) 17 (15)
Usual activities No problem 40 (36) 44 (39)
Some problems 36 (33) 42 (38)
Not able 34 (31) 26 (23)
Pain No pain 43 (39) 40 (36)
Some pain 59 (54) 67 (60)
Extreme pain 8 (7) 5 (4)
Anxiety No anxiety 46 (42) 43 (38)
Some anxiety 57 (52) 62 (56)
Extreme anxiety 7 (6) 7 (6)
Scores for the five dimensions of the EuroQol. Data are numbers (%). Only
participants providing data on all five dimensions are included.
doi:10.1371/journal.pone.0059274.t005
Figure 3. Cumulative survival in the oxygen (black line) and
control (grey line) groups at six months.
doi:10.1371/journal.pone.0059274.g003
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oxygen saturation, lead to a small, but statistically significant
improvement in neurological recovery at one week [7]. While
neurological recovery (i.e. the difference between one-week and
baseline NIHSS scores) was better, NIHSS scores at one week
were the same in both groups. As NIHSS at one week is a strong
predictor of long-term functional outcome [29–31], it is not
surprising that we found no difference in the mRS at six months.
However, baseline NIHSS was imbalanced in this small pilot study
with a higher (worse) NIHSS score in the oxygen group. Patients
in the oxygen group were older, and there were more females, and
this is reflected in lower probability of being free from dependency
at six months on the SSV predictive model. When the six-month
mRS is adjusted for covariate imbalance, oxygen treatment
confers a small (4%), statistically non-significant increase in the
odds of achieving a better (lower) mRS score. As oxygen is a safe
and cheap treatment option, which is available even in very small
hospitals and pre-hospital health settings throughout the world,
even very small differences in outcome could have a significant
impact on stroke outcome worldwide. A very large study is
required to test a small, but worthwhile effect. This is now on-
going (SO2S) [27].
Oxygen was only given for 72 h, and while this is longer than in
the two earlier studies, it could be difficult to discern an effect at six
months, long after the end of the intervention. SO2S therefore has
the main outcome assessment at 90 days, an assessment time point
now suggested as appropriate for acute interventions, but will also
follow patients at 6 and 12 months to see if any effect persists long-
term. The mRS at three months or later has recently been
suggested as the preferred outcome measure by the European
Stroke Organization Outcomes Working group, with other
outcome scales used as supporting scales to corroborate the results
[32]. Findings of the mRS and the other outcome scales in this
study were consistent, supporting validity of the findings. From a
statistical point of view, the additional scales could be considered
redundant, as they do not contribute to the assessment as to
whether the treatment is effective or not. They do, however, put
the results into a ‘real’ life context, and contain information that
stroke survivors consider important [33].
In this trial we assessed six-month outcome by questionnaire.
There were differing rates of missing data on the outcome
measures. The rate tended to be higher for measures that required
a direct response from the participant (e.g. the EuroQol; 23%
missing for the EQ-5D, 39% for the EQ-VAS) and/or were
lengthy or complex to complete (e.g. the NEADL; 33% missing).
The primary outcome measure, the mRS, is a simple scale and can
if necessary be completed by a third party or from information in
the medical notes; accordingly, the rate of missing values on this
measure was relatively low (11%). Those with responses on the
mRS did not differ significantly from those with missing values in
terms of sex (p=0.90), age (p=0.19), or probability of being from
from dependency at 6 months (p=0.10), and although the rate of
missing values was higher in the oxygen group (15%) than in the
control group (8%), this difference was non-significant (p=0.06).
This provides some reassurance that the pattern of missing data on
the primary outcome was not systematic. A number of steps were
taken to establish the primary outcome (mRS) where it was
initially unavailable – by resending questionnaires that had not
been completed, by consulting follow-up records within the
hospital information system and patient notes, and by enquiries
to the patient’s general practitioner, wherever possible. These
strategies have been incorporated and strengthened in the protocol
for the main study [27]. Patients who changed their address and
general practitioner, and who were not readmitted to the hospital,
could not be followed, as we had no access to the follow up
address. Missing values were higher (from 21% to 39%) on other
outcomes, suggesting that these should be interpreted with
caution. Follow-up rates are lower than in recently published
large multicentre trials such as the CLOTS trial [34], the
COSSACS study [35], and IST-3 [36]. The SOS study was an
unfunded pilot, which had insufficient staff to systematically track
non-responders. A recent study has shown that response rates can
be greatly improved with good levels of intermodality agreement
by telephone follow-up of non-responders [37]; this strategy has
been included in the protocol for the main study. Only just over a
third of patients completed the questionnaires unaided, in a
further third it was done by, or with the help of, a friend or
relative. The SOS pilot study has therefore helped us to refine
follow up procedures for SO2S, with computer generated prompts
for follow up, clear guidance on the questionnaire that help of a
relative or friend with completion is acceptable, regular review of
response rates, and back-up telephone calls for repeated non-
responders.
The sample size of this pilot study was the maximum attainable
in relation to available resources, and was not the result of a
sample size calculation. Accordingly, the analyses were not
formally powered, and it should in particular be noted that the
ratio of cases to events in the Cox regression analysis may have
resulted in some overfitting. The sample size for the main study [7]
has been determined through a formal power calculation.
Table 6. The sensitivity analysis.
Intention-to-treat analysis Complete case analysis
Estimate (95% CI) p value n1, n2
a Estimate (95% CI) p value n1, n2
a
Modified Rankin Scaleb 1.04 (0.67, 1.60) 0.86 148, 141 1.07 (0.68, 1.67) 0.78 126, 130
Barthel Indexb 1.50 (0.94, 2.37) 0.09 148, 141 1.50 (0.92, 2.45) 0.11 114, 113
NEADL Scalec 1.59 (23.26, 6.45) 0.52 148, 141 0.64 (23.71, 4.99) 0.77 93, 100
EuroQol EQ-5Dc 20.01 (20.10, 0.07) 0.79 148, 141 2.004 (20.09, 0.10) 0.94 110, 112
EuroQol EQ-VASc 24.40 (211.43, 2.63) 0.22 148, 141 22.35 (29.54, 4.84) 0.52 81, 96
aNumbers for oxygen and control groups, respectively;
bodds ratio (reference category is oxygen);
cmean difference (control–oxygen); CI = confidence interval.
Higher scores on the modified Rankin scale and on the Nottingham Extended Activities of Daily Living (NEADL) Scale are worse; higher scores on the Barthel Index and
EuroQol are better.
doi:10.1371/journal.pone.0059274.t006
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In conclusion, the results of this pilot study do not show a
benefit on long-term outcome, but suggest the possibility a small
improvement in functional outcome when corrected for imbalance
in baseline prognostic factors. It confirms that the duration and
dosing schedule of oxygen in this study are safe. The results have
helped to shape a larger, fully powered study of oxygen
supplementation after acute stroke, which is now in progress.
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